MARKET

ADXN

ADXN

Addex Therapeutics Ltd.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.28
+1.59
+21.84%
Closed 16:00 06/01 EDT
OPEN
8.87
PREV CLOSE
7.28
HIGH
8.87
LOW
8.87
VOLUME
8
TURNOVER
--
52 WEEK HIGH
14.50
52 WEEK LOW
6.19
MARKET CAP
291.37M
P/E (TTM)
-15.3460
1D
5D
1M
3M
1Y
5Y

ADXN News

More
The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 18)
Benzinga · 02/19 12:21
The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 13.)
Benzinga · 02/14 13:23
The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 12)
Benzinga · 02/13 13:05

Industry

Biotechnology & Medical Research
+0.07%
Pharmaceuticals & Medical Research
-0.77%

Hot Stocks

Symbol
Price
%Change

About ADXN

Addex Therapeutics Ltd is a Switzerland-based company, that discovers and develops a class of small molecule drugs, allosteric modulators. Its two products are being investigated in Phase IIa clinical testing: dipraglurant (ADX48621, an mGluR5 negative allosteric modulator or is being developed by the Company to treat Parkinson’s disease levodopa-induced dyskinesia (PD-LID), and ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed by its partner Janssen Pharmaceuticals Inc. to treat schizophrenia. It also is advancing several preclinical programs, including GABA-BR PAM for pain, overactive bladder and other disorders; mGluR4 PAM for Parkinson's, anxiety and other diseases; GLP1R PAM for type 2 diabetes; mGluR2 NAM for treating Alzheimer's disease and depression, and FSHR/LHR NAM for sex hormone dependent tumors and reproductive system disorders. In addition, it has discovery programs to identify allosteric modulators of receptor tyrosine kinase superfamily
More

Webull offers kinds of Addex Therapeutics Ltd stock information, including NASDAQ:ADXN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADXN stock news, and many more online research tools to help you make informed decisions.